CClinicalTrials.gg
CompletedNCT01489930Updated Dec 12, 2011

Effects of Resistance and Endurance Training on Synthesis of Individual Muscle Proteins in Young and Older Adults

An interventional study of Endurance exercise and Resistance exercise in Sarcopenia, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-12-12.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Loss of skeletal muscle strength and skeletal muscle mass occurs with of aging. This are-related decline in skeletal muscle mass and skeletal muscle strength is a major underlying factor contributing to many of the metabolic disorders and frailty of the investigators rapidly expanding aging population. Endurance (aerobic) and resistance exercise training programs have been shown to effectively reverse the age-related decline in metabolic and contractile muscle functions. The investigators will measure synthesis rates of individual muscle proteins in 36 each of young (18-30 yrs) and 36 older (> 65 yrs) people to determine their response to 8 weeks each of endurance, resistance, combined endurance and resistance training, or placebo exercise training.

Hypotheses.

  1. to measure fractional synthesis rates of multiple muscle proteins and identify those that are enhanced by an endurance exercise program
  2. to determine whether changes in protein synthesis in response to endurance exercise programs are dependent on age
  3. to measure fractional muscle synthesis rates of multiple muscle proteins and to identify those that are enhanced by a resistance exercise program
  4. to determine whether changes in protein synthesis in response to resistance exercise programs are dependent on age
02

Conditions studied

  • Sarcopenia

Browse trials for

Keywords

  • Exercise
  • Aging
  • Sarcopenia
  • Mitochondria
03

In context

Sarcopenia

1,208 studies on the registry are indexed under Sarcopenia; 402 are open to participants now.

This study's enrollment of 67 is above the median of 60 across 775 interventional studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy
  • 18 to 30 or >65 years
  • Males and Females

Exclusion criteria

Exclusion Criteria:

  • Regular Exercise Program
  • Smoking
  • Cardiometabolic Disease (diabetes, cardiovascular disease, thyroid disorders)
  • Drugs known to impair metabolic function (beta blockers, steroids)
  • Allergies to lidocaine
  • Physical disability that precludes exercise
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Endurance Exercise

    Participants will perform 8-weeks of moderate intensity endurance (cycling) exercise

    Behavioral: Endurance exercise

  • Experimental
    Resistance Exercise

    Participants will perform 8-weeks of whole-body resistance exercise training.

    Behavioral: Resistance exercise

  • Experimental
    Control / Combined Training

    Participants will perform 8-weeks of no exercise, followed by an additional 8-weeks of combined endurance plus resistance exercise training.

    Behavioral: Control/Combined training

Interventions

  • BehavioralEndurance exercise

    Participants will perform 8-weeks of endurance exercise training. Participants will train 5 days per week for 60 min at 65% of VO2 peak.

  • BehavioralResistance exercise

    Participants will perform 8-weeks of resistance exercise training. Participants will train 4 days per week for \~60 min. Two days will focus on lower body resistance training and two days will focus on upper body.

  • BehavioralControl/Combined training

    Participants will perform 8-weeks of no exercise (control), followed by 8-weeks of combined endurance and resistance training. Participants will endurance train 5 days per week for 30 min at 65% of VO2 peak and resistance train 4 days per week for 30 min.

06

What researchers measure

Primary outcomes

  1. Skeletal Muscle Protein Synthesis

    The investigators will determine the change from baseline in skeletal muscle protein synthesis. Measurments will be performed at baseline and following 8 weeks of exercise training.

    Time frame: Measured at week 0 (baseline) and week 8

Secondary outcomes

  1. Mitochondrial Function

    The investigators will determine the change from baseline in mitochondrial function. Measurments will be performed at baseline and following 8 weeks of exercise training.

    Time frame: Measured at week 0 (baseline) and week 8

07

Study locations

1 site
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
08

References and documents

Publications

  • Irving BA, Lanza IR, Henderson GC, Rao RR, Spiegelman BM, Nair KS. Combined training enhances skeletal muscle mitochondrial oxidative capacity independent of age. J Clin Endocrinol Metab. 2015 Apr;100(4):1654-63. doi: 10.1210/jc.2014-3081. Epub 2015 Jan 19. Erratum In: J Clin Endocrinol Metab. 2023 Nov 17;108(12):e1763. doi: 10.1210/clinem/dgad474. PubMed 25599385 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01489930
Lead sponsor
Mayo Clinic
Responsible party
K. Sreekumaran Nair (Professor of Medicine, Mayo Clinic) — Principal investigator
First posted
Dec 12, 2011
Start date
May 2008
Primary completion
Feb 2011
Completion
Feb 2011
Last update
Dec 12, 2011

Study contacts

K. Sreekumaran Nair, MD, PD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion